Loading data for SMMT — first visit, this takes a few seconds.

Summit Therapeutics Inc.

NasdaqGM: SMMT · Real-Time Price · USD
13.73
-0.60 (-4.19%)
At close: Aug 28, 2026, 3:59 PM
13.71
-0.11%
After-hours: 7:59 PM

The price, the headline numbers and the latest news, in one place.

Summit Therapeutics Inc. (SMMT) Stock Price, Analysis & Data

-4.19%
Bid12.56
Market Cap10.95B
Revenue (ttm)n/a
Net Income (ttm)-856.09M
-1.24
-1.06
n/a
-11.41
P/B (ttm)17.29
P/S (ttm)n/a
Earnings DateOct 19, 2026
Ask14.55
Volume3,891,333
Avg. Volume (20D)5,489,179
Open14.11
Previous Close14.33
Day's Range13.43 - 14.24
52-Week Range12.07 - 29.23
Analystn/a
Price Targetn/a
Dividendsn/a
Ex-Dividend Daten/a

About SMMT

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab ...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 5, 2015
Employees 265
Stock Exchange NasdaqGM
Ticker Symbol SMMT
Full Company Profile

Financial Performance

In 2025, Summit Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -1.08B, an increase of 387.81%.

Financial Statements

Earnings Surprise

Summit Therapeutics has released their quarterly earnings on Jul 23, 2026:
  • Revenue of $0 misses estimates by $0, with NaN% YoY growth.
  • EPS of -0.21 misses estimates by 0.00, with 63.16% YoY growth.
Summit Therapeutics Inc. is scheduled to release its earnings on Oct 19, 2026, after market closes.
Analysts project revenue of ... Upgrade





Page 1 of 2